Logo image of PRE

PRENETICS GLOBAL LTD-CL A (PRE) Stock Fundamental Analysis

NASDAQ:PRE - Nasdaq - KYG722451229 - Common Stock - Currency: USD

5.33  -0.02 (-0.37%)

Fundamental Rating

3

PRE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 108 industry peers in the Health Care Providers & Services industry. The financial health of PRE is average, but there are quite some concerns on its profitability. PRE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PRE had negative earnings in the past year.
PRE had negative earnings in each of the past 5 years.
In the past 5 years PRE reported 4 times negative operating cash flow.
PRE Yearly Net Income VS EBIT VS OCF VS FCFPRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -25.50%, PRE is doing worse than 81.31% of the companies in the same industry.
PRE has a Return On Equity of -31.41%. This is in the lower half of the industry: PRE underperforms 66.36% of its industry peers.
Industry RankSector Rank
ROA -25.5%
ROE -31.41%
ROIC N/A
ROA(3y)-28.89%
ROA(5y)-31.4%
ROE(3y)-37.26%
ROE(5y)-47.44%
ROIC(3y)N/A
ROIC(5y)N/A
PRE Yearly ROA, ROE, ROICPRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -20 -40 -60 -80 -100

1.3 Margins

PRE has a better Gross Margin (42.48%) than 68.22% of its industry peers.
PRE's Gross Margin has been stable in the last couple of years.
PRE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5YN/A
PRE Yearly Profit, Operating, Gross MarginsPRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

5

2. Health

2.1 Basic Checks

PRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRE has more shares outstanding
PRE has a better debt/assets ratio than last year.
PRE Yearly Shares OutstandingPRE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
PRE Yearly Total Debt VS Total AssetsPRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 1.70, we must say that PRE is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PRE (1.70) is comparable to the rest of the industry.
PRE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, PRE belongs to the top of the industry, outperforming 83.18% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.7
ROIC/WACCN/A
WACC6.45%
PRE Yearly LT Debt VS Equity VS FCFPRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 2.37 indicates that PRE has no problem at all paying its short term obligations.
PRE has a Current ratio of 2.37. This is in the better half of the industry: PRE outperforms 78.50% of its industry peers.
A Quick Ratio of 2.29 indicates that PRE has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.29, PRE belongs to the top of the industry, outperforming 80.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.37
Quick Ratio 2.29
PRE Yearly Current Assets VS Current LiabilitesPRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.17% over the past year.
PRE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -92.12%.
The Revenue for PRE have been decreasing by -30.65% on average. This is quite bad
EPS 1Y (TTM)85.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-950%
Revenue 1Y (TTM)-92.12%
Revenue growth 3Y-30.65%
Revenue growth 5YN/A
Sales Q2Q%59.86%

3.2 Future

The Earnings Per Share is expected to grow by 32.28% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 17.20% on average over the next years. This is quite good.
EPS Next Y20.64%
EPS Next 2Y32.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-56.74%
Revenue Next 2Y17.2%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PRE Yearly Revenue VS EstimatesPRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
PRE Yearly EPS VS EstimatesPRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRE Price Earnings VS Forward Price EarningsPRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRE Per share dataPRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PRE's earnings are expected to grow with 32.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.28%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PRE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PRENETICS GLOBAL LTD-CL A

NASDAQ:PRE (2/21/2025, 8:00:01 PM)

5.33

-0.02 (-0.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-27 2024-11-27/bmo
Earnings (Next)N/A N/A
Inst Owners13.5%
Inst Owner Change-100%
Ins Owners15.63%
Ins Owner Change0%
Market Cap65.13M
Analysts80
Price Target9.18 (72.23%)
Short Float %0.39%
Short Ratio1.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.43%
Min EPS beat(2)-107.26%
Max EPS beat(2)90.4%
EPS beat(4)1
Avg EPS beat(4)-32.6%
Min EPS beat(4)-107.26%
Max EPS beat(4)90.4%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-71.46%
Min Revenue beat(2)-73.45%
Max Revenue beat(2)-69.46%
Revenue beat(4)0
Avg Revenue beat(4)-62.2%
Min Revenue beat(4)-78.3%
Max Revenue beat(4)-27.58%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.6%
EPS NY rev (3m)0.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.93
P/FCF N/A
P/OCF N/A
P/B 0.32
P/tB 0.4
EV/EBITDA N/A
EPS(TTM)-4.2
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.76
BVpS16.89
TBVpS13.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.5%
ROE -31.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.48%
FCFM N/A
ROA(3y)-28.89%
ROA(5y)-31.4%
ROE(3y)-37.26%
ROE(5y)-47.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.16%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.37
Quick Ratio 2.29
Altman-Z 1.7
F-ScoreN/A
WACC6.45%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-950%
EPS Next Y20.64%
EPS Next 2Y32.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-92.12%
Revenue growth 3Y-30.65%
Revenue growth 5YN/A
Sales Q2Q%59.86%
Revenue Next Year-56.74%
Revenue Next 2Y17.2%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19587.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A